II. Indications
- Insomnia (as adjunct to SSRI)
-
Impotence
- See Impotence Management for more effective agents
III. Mechanism
- Triazolopyridine derivative
- Unrelated to Tricyclic Antidepressants
- Phenylpiperazine Antidepressant (Serzone prototype)
-
Serotonin Antagonist and Reuptake Inhibitor (SARI)
- Blocks 5-HT-2 postsynaptic receptor
- Low dose: Serotonin receptor Antagonist
- High dose: Serotonin Agonist
- Weaker than SSRIs as a Serotonin reuptake inhibitor
IV. Pharmacokinetics
- Serum Half Life: 4 to 9 hours
- Therapeutic plasma level: 800 to 1600
V. Efficacy: Major Depression
- As effective as Fluoxetine, Tricyclic Antidepressants
VI. Background
- Cost: $34 per month (generic)
VII. Dosing
-
Sleep
- Dose: 25-100 mg PO qhs
- Average: 50 mg PO qhs
-
Major Depression
- Start: 50 to 150 mg per day in divided doses
- Effective dose: 400 to 600 mg in divided doses
VIII. Adverse Effects
- Sedation
- Limits use as an Antidepressant
- Useful in Major Depression with Insomnia
-
Priapism
- See Priapism Management
- Serotonin Syndrome
- Cardiac Arrhythmia
-
Orthostatic Hypotension (Dizziness)
- Minimize by administering with food
X. Toxicity
- Less toxic in Overdose than Tricyclic Antidepressants
- Lower Incidence of Anticholinergic Toxicity
XI. References
- Sundberg (1995) Depression Primary Care, PGM, p. 45-57
Images: Related links to external sites (from Bing)
Related Studies
| trazodone (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| TRAZODONE 100 MG TABLET | Generic | $0.07 each |
| TRAZODONE 150 MG TABLET | Generic | $0.12 each |
| TRAZODONE 300 MG TABLET | Generic | $1.40 each |
| TRAZODONE 50 MG TABLET | Generic | $0.04 each |
Ontology: Trazodone (C0040805)
| Definition (CHV) | a kind of depression treatment drug |
| Definition (CHV) | a kind of depression treatment drug |
| Definition (NCI) | A synthetic triazolopyridine derivative, antidepressant and sedative Trazodone acts as a serotonin uptake inhibitor, chemically unrelated to tricyclic, tetracyclic, or other antidepressants. It is effective in patients with schizoaffective disorders; major depressive disorders; and depressive disorders associated with insomnia and anxiety. (NCI04) |
| Definition (MSH) | A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309) |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D014196 |
| SnomedCT | 372829000, 7336002 |
| LNC | LP16297-1, MTHU005053 |
| English | Tradozone, Trazodone, 1,2,4-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-, Searle Brand of Trazodone Hydrochloride, Trazodone [Chemical/Ingredient], tradozone, traZODone, TRAZODONE, trazodone, Trazodone (product), Trazodone (substance) |
| Swedish | Trazodon |
| Czech | trazodon |
| Finnish | Tratsodoni |
| Russian | TRAZODON, ТРАЗОДОН |
| Japanese | トラゾドン |
| Polish | Trazodon |
| Spanish | trazodona (producto), trazodona (sustancia), trazodona, Trazodona |
| French | Trazodone |
| German | Trazodon |
| Italian | Trazodone |
| Portuguese | Trazodona |
Ontology: Desyrel (C0701914)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D014196 |
| English | desyrel, Desyrel, Apothecon Brand of Trazodone Hydrochloride, Bristol Myers Squibb Brand of Trazodone Hydrochloride, Bristol-Myers Squibb Brand of Trazodone Hydrochloride |
